Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1168

Tocilizumab

Home » Tocilizumab

Background of Tocilizumab

Tocilizumab is a recombinant humanized monoclonal antibody that inhibits the IL-6 receptor, used to treat various inflammatory and autoimmune conditions. Marketed as Actemra, this biologic medication is approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), adults with systemic sclerosis complicated by interstitial lung disease, and individuals aged 2 and above with polyarticular juvenile idiopathic arthritis (PJIA) or systemic juvenile idiopathic arthritis (SJIA). Tocilizumab works by blocking the inflammatory protein IL-6, thereby alleviating joint pain, reducing swelling from arthritis, and mitigating other inflammation-related symptoms.

Specifications

Catalog Number:
KB-1168
Antibody Name:
Tocilizumab
Isotype:
Human IgG1, kappa
FC Muations:
Wild Type
Target:
IL6R
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, Bao M, Rowell L, Burmester GR, Kivitz A: Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017 Apr;57(4):459-468.